FDA Inspection 1248325 — Apnar Pharma LP
The FDA completed an inspection of Apnar Pharma LP on August 16, 2024 in Chino, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 16, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Chino, CA (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)